Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Entella
- Development stage
- Unknown
- Lead developer
- Espad Pharmed
- Administration
- Dermal, Subcutaneous, Intracutaneous
01
Overview
Entella is a hyaluronic acid-based dermal filler developed and manufactured by Espad Pharmed for aesthetic and cosmetic applications. It is specifically indicated for soft-tissue augmentation, wrinkle correction, and facial volumization. Administered via dermal, subcutaneous, or intracutaneous injection, Entella works by physically filling space within the tissue and binding water molecules to restore lost volume and smooth facial contours. As a cross-linked hyaluronic acid gel, it provides a non-surgical option for addressing age-related facial changes and enhancing aesthetic features. The product is part of a broader portfolio of aesthetic injectables produced by Espad Pharmed, which focuses on cosmetic medicine rather than traditional therapeutic pharmaceutical development.
- Brand names
- Entella
Beyond the preview
Go deeper on Entella.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Entella.